Versant Capital Management’s Viridian Therapeutics VRDN Stock Holding History

Versant Capital Management’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.72K	Buy	148 +14	+10%	+$226	﹤0.01%	2528
2026 Q1	$2.62K	Hold	134	–	–	﹤0.01%	2521
2025 Q4	$4.17K	Hold	134	–	–	﹤0.01%	2316
2025 Q3	$2.89K	Hold	134	–	–	﹤0.01%	2346
2025 Q2	$1.87K	Sell	134 -179	-57%	-$2.43K	﹤0.01%	2394
2025 Q1	$4.22K	Buy	313 +231	+282%	+$3.94K	﹤0.01%	2083
2024 Q4	$1.57K	Buy	+82	New	+$1.78K	﹤0.01%	2106

Other funds holding VRDN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Versant Capital Management's VRDN Position: Q2 2026 in Review

Versant Capital Management increased its Viridian Therapeutics (VRDN) stake by 10% in Q2 2026, buying an estimated $226 and bringing the position to 148 shares worth $2.72K. The position accounts for ﹤0.01% of the portfolio, ranked #2528.

Versant Capital Management first reported a position in VRDN in Q4 2024 and has held it in 7 quarters since. The position peaked at $4.22K in Q1 2025. 214 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

Versant Capital Management held 148 shares of Viridian Therapeutics worth $2.72K as of Q2 2026.
Versant Capital Management bought 14 Viridian Therapeutics shares in Q2 2026, an estimated $226.
Viridian Therapeutics made up ﹤0.01% of Versant Capital Management's portfolio in Q2 2026, its #2528 holding.
Versant Capital Management first reported a position in Viridian Therapeutics in Q4 2024 and has held it in 7 quarters since.
Versant Capital Management's Viridian Therapeutics position peaked at $4.22K in Q1 2025.
214 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.